giant cell arteritis
Rheumatology · 2018–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Tocilizumab biosimilar requested for listing under the same indications as the reference biologic Actemra, including active giant cell arteritis, systemic… | Nov 2025 | Recommended with restriction | none received |
| tocilizumab Treatment of patients with active giant cell arteritis (GCA) in combination with a tapering course of corticosteroids for a maximum of 12 months. | Mar 2019 | Recommended with restriction | none received |
| tocilizumab Treatment of patients with new-onset or relapsed giant cell arteritis (GCA). | Nov 2018 | Deferred | 1 individuals |
What the PBS pays
$70M in government benefit over 2024–25, across 91,499 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| tocilizumab | $69.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tocilizumabTocilizumab for treating giant cell arteritis | TA518 | recommended restricted | 2018-04 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| cortisoneCORTATE cortisone acetate 25mg tablet bottle | 1991 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.